|
Pervin Anklesaria, Ph.D., Vice President Therapeutic Development
Pervin Anklesaria joined Targeted Genetics Corporation in 1993 and currently leads the clinical, regulatory, quality, pre-clinical and project management groups. Dr. Anklesaria also served as Vice President of Research, Director of Research and Development Administration and Staff Scientist with the Company prior to assuming her current position in 2002. Prior, Dr. Anklesaria was an Assistant Professor in the Department of Radiation Oncology at the University Massachusetts Medical Center where studied stem cell biology and managed the laboratory and staff activities as an independent investigator. Dr. Anklesaria received a B.S. in Microbiology and Chemistry, a M.S. in Biophysics and a Ph.D. in Cell Biology from the University of Bombay, India.
Richard W. Peluso, Ph.D., Vice President, Process Development
Richard Peluso has been with Targeted Genetics since 2000. Before joining Targeted Genetics he worked for Genovo, a private gene therapy company near Philadelphia. Dr. Peluso worked for two years prior to Genovo for Quality Biotech/ViroMed, a contract biosafety testing company. Prior to that he held academic positions at several medical schools, the most recent the Mount Sinai School of Medicine in New York, where he was an associate professor and ran an academic research lab. Richard obtained a PhD from The Rockefeller University in New York in Virology with Professors Purnell Choppin and Robert Lamb. Richard serves on the editorial board of Virology and Human Gene Therapy.
B.G. Susan Robinson, Vice President, Business Development
Susan Robinson leads the licensing and partnering activities for Targeted Genetics and is integrally involved in the M&A activities and strategic planning functions for the company. Prior to joining Targeted Genetics in March 2000, Ms. Robinson was employed as Director, Business Development at Genzyme Molecular Oncology , a tracking stock of Genzyme Corporation. In her business development roles she has completed multiple academic and corporate technology licenses, sponsored research agreements, pharma/biotech product development collaboration agreements and an acquisition. Prior to Genzyme, and over a nine year period, Ms. Robinson held increasingly responsible positions in corporate development and Corporate Communications for two biotech companies. In these positions, she was involved in strategic planning, public and private financing efforts, interactions with sell and buyside analysts and the creation and delivery of investor presentations and press releases. Ms. Robinson graduated with a B.S. in Biology from Yale University in 1983. | 